)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Eckert & Ziegler
Eckert & Ziegler (EUZ) investor relations material
Eckert & Ziegler AGM 2026 presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 presentation summary26 Jun, 2026
Market environment and growth potential
Nuclear medicine market projected to reach $26 billion by 2030, with annual growth of 15% expected until then.
Significant investments from major pharma companies highlight strong sector momentum.
Demand for radiopharmaceuticals continues to rise, driven by new therapies and diagnostic isotopes.
Core competencies and strategic positioning
Leading supplier of Ga-68 generators, with approvals in key global markets.
Expansion in therapeutic isotopes such as Lu-177 and Y-90, with new approvals and product launches planned.
Pioneer in Actinium-225, targeting GMP quality by early 2025 and first commercial drug by 2028.
Broad service offering includes contract manufacturing, infrastructure, and equipment for radiopharmaceuticals.
Partnerships and milestones
Long-term contracts and strategic partnerships with companies like Novartis, Actinium Pharmaceuticals, and Bicycle Therapeutics.
Collaboration with Molecular Partners to advance next-generation radiopharmaceutical platforms.
Key product approvals and manufacturing agreements in Japan and the US support global expansion.
Value of the early-stage platform partner model
Reasons for the 2026 Ac-225 license revenue drop
Recovery plan for high-margin industrial sources
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Eckert & Ziegler
- Net income up 28% to €29.9M, Medical segment drives growth, 2025 outlook reaffirmed.EUZ
Q3 202530 Jun 2026 - Revenue up 17% and EBIT up 24%, with strategic spin-off and new contracts supporting growth.EUZQ3 20241 Jun 2026
- Revenue and net profit rose 7% year-over-year, led by Medical segment and radiopharmaceuticals.EUZQ1 202618 May 2026
- Net income up 19% and Medical segment margins improved; 2025 guidance reaffirmed.EUZQ2 202515 May 2026
- Record 2025 revenue and EBIT growth led by Medical and radiopharmaceuticals, with global expansion ahead.EUZQ4 202530 Mar 2026
- Record revenue and EBIT growth driven by radiopharma and medical segments, with strong 2024 outlook.EUZQ4 20243 Feb 2026
- Radiopharmaceuticals and gallium generators fueled double-digit growth and global expansion.EUZGerman Equity Forum 20252 Feb 2026
- Revenue up 23%, EBIT up 44%, and 2024 profit guidance raised to €55M.EUZQ2 20241 Feb 2026
- Medical segment drives growth as radiopharmaceuticals expand and 2025 outlook stays positive.EUZIV. ICF Bank Small-/MidCap-Conference Presentation26 Jan 2026
Next Eckert & Ziegler earnings date
Q2 202613 Aug, 2026
Eckert & Ziegler
Next Eckert & Ziegler earnings date
Q2 202613 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage